The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

By Isabel M. Chu, L. Hengst, J. Slingerland. Nature Reviews. Cancer, 2008

1,048 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Myc and cell cycle control. (2015, neutral): “to poor prognosis [196,197].”
Therapy-induced senescence in cancer. (2010, background): “In cancer, the downregulation of p27Kip1 and expression of its regulator ubiquitin ligase SKP2 has been identified in prostate and other cancers (92,93), as well as in precancerous lesions (17).”
Biological determinants of endocrine resistance in breast cancer (2009, background): “There is also more limited evidence for a relationship between the overexpression of cyclin E1, RB inactivation and reduced expression of p27 and clinical respons”
Intrinsically disordered proteins: regulation and disease. (2011, background): “Such mechanisms can result in increased abundance and longer half-life via change in cellular localization or by protection from the degradation machinery as in certain phosphorylated forms of p27 [48].”